{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:48:04Z","timestamp":1761490084135},"reference-count":57,"publisher":"Impact Journals, LLC","issue":"43","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,10,25]]},"DOI":"10.18632\/oncotarget.11566","type":"journal-article","created":{"date-parts":[[2016,8,24]],"date-time":"2016-08-24T15:58:25Z","timestamp":1472054305000},"page":"69945-69960","source":"Crossref","is-referenced-by-count":4,"title":["Identification of Bisindolylmaleimide IX as a potential agent to treat drug-resistant BCR-ABL positive leukemia"],"prefix":"10.18632","volume":"7","author":[{"given":"Xin","family":"Zhang","sequence":"first","affiliation":[{"name":"Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Ministry of Education, Shanghai Jiao Tong University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deyong","family":"Jia","sequence":"additional","affiliation":[{"name":"Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Ministry of Education, Shanghai Jiao Tong University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junping","family":"Ao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Ministry of Education, Shanghai Jiao Tong University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zang","sequence":"additional","affiliation":[{"name":"National Center for Drug Screening, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Azam","sequence":"additional","affiliation":[{"name":"Divisions of Pathology, Hematology and Cancer Biology, Cancer and Blood Disease Institute, Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samy L.","family":"Habib","sequence":"additional","affiliation":[{"name":"South Texas Veterans Health Care System and Department of Cellular and Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[{"name":"National Center for Drug Screening, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinsen","family":"Ruan","sequence":"additional","affiliation":[{"name":"Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Ministry of Education, Shanghai Jiao Tong University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Jia","sequence":"additional","affiliation":[{"name":"Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Ministry of Education, Shanghai Jiao Tong University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, National University of Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baojie","family":"Li","sequence":"additional","affiliation":[{"name":"Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Ministry of Education, Shanghai Jiao Tong University, Shanghai, China"},{"name":"Translational Medical Center for Stem Cell Therapy, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,8,24]]},"reference":[{"key":"1","first-page":"69","article-title":"Global cancer statistics","volume":"1","author":"Forman","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/onc.2010.460","article-title":"Towards novel paradigms for cancer therapy","volume":"30","author":"Gronemeyer","year":"2011","journal-title":"Oncogene"},{"key":"3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev.immunol.22.012703.104753","article-title":"The BCR-ABL story: bench to bedside and back","volume":"22","author":"Witte","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"4","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/ajh.23691","article-title":"Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management","volume":"89","author":"Kantarjian","year":"2014","journal-title":"Am J Hematol"},{"key":"5","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cell.2009.02.024","article-title":"Principles of cancer therapy: oncogene and non-oncogene addiction","volume":"136","author":"Elledge","year":"2009","journal-title":"Cell"},{"key":"6","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/nm1009-1158","article-title":"Shifting paradigms: the seeds of oncogene addiction","volume":"10","author":"Sawyers","year":"2009","journal-title":"Nat Med"},{"key":"7","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Druker","year":"2005","journal-title":"Blood"},{"key":"8","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrclinonc.2009.112","article-title":"Imatinib and beyond--exploring the full potential of targeted therapy for CML","volume":"6","author":"Cortes","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"9","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/leu.2008.78","article-title":"BCR\/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress","volume":"22","author":"Skorski","year":"2008","journal-title":"Leukemia"},{"key":"10","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/leu.2010.67","article-title":"BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia","volume":"24","author":"Carroll","year":"2010","journal-title":"Leukemia"},{"key":"11","doi-asserted-by":"crossref","first-page":"6180","DOI":"10.1182\/blood-2012-05-423897","article-title":"BCR\/ABL and chromosomal instability: debate resolved","volume":"119","author":"Carroll","year":"2012","journal-title":"Blood"},{"key":"12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2005-07-2815","article-title":"BCR\/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance","volume":"108","author":"Skorski","year":"2006","journal-title":"Blood"},{"key":"13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1535-6108(04)00056-X","article-title":"BCR\/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint","volume":"5","author":"Carroll","year":"2004","journal-title":"Cancer Cell"},{"key":"14","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1158\/1078-0432.CCR-10-2922","article-title":"Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy","volume":"17","author":"Cortes","year":"2011","journal-title":"Clin Cancer Res"},{"key":"15","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Talpaz","year":"2012","journal-title":"New Engl J Med"},{"key":"16","doi-asserted-by":"crossref","first-page":"5828","DOI":"10.1158\/1078-0432.CCR-13-0258","article-title":"Ponatinib--a step forward in overcoming resistance in chronic myeloid leukemia","volume":"19","author":"Licht","year":"2013","journal-title":"Clin Cancer Res"},{"key":"17","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.18632\/oncotarget.2837","article-title":"HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation","volume":"6","author":"Kim","year":"2015","journal-title":"Oncotarget"},{"key":"18","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrc2169","article-title":"CDC25 phosphatases in cancer cells: key players? Good targets?","volume":"7","author":"Ducommun","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0065-230X(01)83007-4","article-title":"ATM: genome stability, neuronal development, and cancer cross paths","volume":"83","author":"Kastan","year":"2001","journal-title":"Adv Cancer Res"},{"key":"20","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1021\/bi700026j","article-title":"Cdc25 phosphatases: structure, specificity, and mechanism","volume":"46","author":"Rudolph","year":"2007","journal-title":"Biochemistry"},{"key":"21","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35042675","article-title":"Surfing the p53 network","volume":"408","author":"Levine","year":"2000","journal-title":"Nature"},{"key":"22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrm2147","article-title":"p53 in health and disease","volume":"8","author":"Lane","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"23","first-page":"107","article-title":"New insights into p53 based therapy","volume":"12","author":"Cheok","year":"2011","journal-title":"Discov Med"},{"key":"24","doi-asserted-by":"crossref","first-page":"15771","DOI":"10.1016\/S0021-9258(18)98476-0","article-title":"The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C","volume":"266","author":"Loriolle","year":"1991","journal-title":"J Biol Chem"},{"key":"25","first-page":"21","article-title":"Bisindolylmaleimides in anti-cancer therapy - more than PKC inhibitors","volume":"53","author":"Orzechowski","year":"2008","journal-title":"Adv Med Sci"},{"key":"26","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/CCO.0b013e3282f10a00","article-title":"Enzastaurin","volume":"19","author":"Rosen","year":"2007","journal-title":"Curr Opin Oncol"},{"key":"27","doi-asserted-by":"crossref","first-page":"s4641","DOI":"10.1158\/1078-0432.CCR-07-0538","article-title":"Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancer","volume":"13","author":"Lahn","year":"2007","journal-title":"Clin Cancer Res"},{"key":"28","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ccr.2006.09.014","article-title":"A common signaling cascade may underlie \u201caddiction\u201d to the Src, BCR-ABL, and EGF receptor oncogenes","volume":"10","author":"Settleman","year":"2006","journal-title":"Cancer Cell"},{"key":"29","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/nature03482","article-title":"DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis","volume":"434","author":"Bartek","year":"2005","journal-title":"Nature"},{"key":"30","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1038\/sj.onc.1210881","article-title":"DNA damage signalling guards against activated oncogenes and tumour progression","volume":"26","author":"Lukas","year":"2007","journal-title":"Oncogene"},{"key":"31","doi-asserted-by":"crossref","first-page":"e62527","DOI":"10.1371\/journal.pone.0062527","article-title":"Identification of 5-Iodotubercidin as a genotoxic drug with anti-cancer potential","volume":"8","author":"Li","year":"2013","journal-title":"PloS One"},{"key":"32","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0006-2952(98)00045-8","article-title":"Induction of apoptosis in glioblastoma cells by inhibition of protein kinase C and its association with the rapid accumulation of p53 and induction of the insulin-like growth factor-1-binding protein-3","volume":"55","author":"Glazer","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"33","first-page":"426","article-title":"Focusing on foci: H2AX and the recruitment of DNA-damage response factors","volume":"2","author":"Nussenzweig","year":"2003","journal-title":"Cell Cycle"},{"key":"34","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1021\/jm950465d","article-title":"Bisindolylmaleimides linked to DNA minor groove binding lexitropsins: synthesis, inhibitory activity against topoisomerase I, and biological evaluation","volume":"39","author":"Lown","year":"1996","journal-title":"J Med Chem"},{"key":"35","first-page":"18","article-title":"Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets","volume":"106","author":"El-Khamisy","year":"2011","journal-title":"Brit J Cancer"},{"key":"36","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.2174\/1381612811319130016","article-title":"Recent developments of DNA poisons--human DNA topoisomerase IIalpha inhibitors--as anticancer agents","volume":"19","author":"Solmajer","year":"2013","journal-title":"Curr Pharm Design"},{"key":"37","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1073\/pnas.0602402103","article-title":"Loss of p53 impedes the antileukemic response to BCR-ABL inhibition","volume":"103","author":"Lowe","year":"2006","journal-title":"P Natl Acad Sci USA"},{"key":"38","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.1158\/0008-5472.CAN-10-4433","article-title":"A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients","volume":"71","author":"Wartmann","year":"2011","journal-title":"Cancer Res"},{"key":"39","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood-2007-07-104257","article-title":"Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks","volume":"112","author":"Rassool","year":"2008","journal-title":"Blood"},{"key":"40","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1182\/blood.V104.11.712.712","article-title":"BCR\/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks","volume":"104","author":"Skorski","year":"2004","journal-title":"Blood"},{"key":"41","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1182\/blood-2005-07-2966","article-title":"Adaphostin-induced oxidative stress overcomes BCR\/ABL mutation-dependent and -independent imatinib resistance","volume":"107","author":"Kaufmann","year":"2006","journal-title":"Blood"},{"key":"42","doi-asserted-by":"crossref","first-page":"24273","DOI":"10.1074\/jbc.M002094200","article-title":"The BCR\/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells","volume":"275","author":"Griffin","year":"2000","journal-title":"J Biol Chem"},{"key":"43","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1158\/1078-0432.CCR-10-1613","article-title":"Molecular pathways: BCR-ABL","volume":"18","author":"Saglio","year":"2012","journal-title":"Clin Cancer Res"},{"key":"44","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/leu.2008.27","article-title":"Targeting survival cascades induced by activation of Ras\/Raf\/MEK\/ERK, PI3K\/PTEN\/Akt\/mTOR and Jak\/STAT pathways for effective leukemia therapy","volume":"22","author":"Martelli","year":"2008","journal-title":"Leukemia"},{"key":"45","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/leu.2011.67","article-title":"The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem\/progenitor cells","volume":"25","author":"Holyoake","year":"2011","journal-title":"Leukemia"},{"key":"46","doi-asserted-by":"publisher","first-page":"20231","DOI":"10.18632\/oncotarget.4047","article-title":"Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with abelson tyrosine kinase inhibitors, against break point cluster region-c-abelson-positive leukemia cells","volume":"6","author":"Ohyashiki","year":"2015","journal-title":"Oncotarget"},{"key":"47","doi-asserted-by":"publisher","first-page":"8637","DOI":"10.18632\/oncotarget.2353","article-title":"Selective JAK2\/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem\/progenitor cells","volume":"5","author":"Jiang","year":"2014","journal-title":"Oncotarget"},{"key":"48","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1126\/science.280.5360.109","article-title":"Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C","volume":"280","author":"Marshall","year":"1998","journal-title":"Science"},{"key":"49","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.tibs.2010.06.001","article-title":"Partner exchange: protein-protein interactions in the Raf pathway","volume":"35","author":"Baccarini","year":"2010","journal-title":"Trends Biochem Sci"},{"key":"50","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1517\/13543784.17.6.939","article-title":"Enzastaurin","volume":"17","author":"LaCasce","year":"2008","journal-title":"Expert Opin Inv Drug"},{"key":"51","doi-asserted-by":"crossref","first-page":"33213","DOI":"10.1074\/jbc.M204612200","article-title":"Bisindolylmaleimide IX facilitates tumor necrosis factor receptor family-mediated cell death and acts as an inhibitor of transcription","volume":"277","author":"Cohen","year":"2002","journal-title":"J Biol Chem"},{"key":"52","doi-asserted-by":"crossref","first-page":"266","DOI":"10.4161\/cbt.2.3.361","article-title":"Bisindolylmaleimide IX Induces Reversible and Time-Dependent Tumor Necrosis Factor Receptor Family-Mediated Caspase Activation and Cell Death","volume":"2","author":"Cohen","year":"2003","journal-title":"Cancer Biol Ther"},{"key":"53","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1038\/sj.leu.2403088","article-title":"Bisindolylmaleimide IX is a potent inducer of apoptosis in chronic lymphocytic leukaemic cells and activates cleavage of Mcl-1","volume":"17","author":"Cohen","year":"2003","journal-title":"Leukemia"},{"key":"54","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1182\/blood.V95.11.3478","article-title":"Expression of c-FLIP(L) and resistance to CD95-mediated apoptosis of monocyte-derived dendritic cells: inhibition by bisindolylmaleimide","volume":"95","author":"Goldman","year":"2000","journal-title":"Blood"},{"key":"55","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1016\/j.bmcl.2005.04.015","article-title":"Structure-activity relationship of N-methyl-bisindolylmaleimide derivatives as cell death inhibitors","volume":"15","author":"Sodeoka","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"56","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1016\/j.bmcl.2007.02.059","article-title":"Novel bis(indolyl)maleimide pyridinophanes that are potent, selective inhibitors of glycogen synthase kinase-3","volume":"17","author":"Maryanoff","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"57","doi-asserted-by":"crossref","first-page":"51851","DOI":"10.1074\/jbc.M404396200","article-title":"Phosphorylation of DNA topoisomerase I by the c-Abl tyrosine kinase confers camptothecin sensitivity","volume":"279","author":"Bharti","year":"2004","journal-title":"J Biol Chem"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.11566","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:06:17Z","timestamp":1657152377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.11566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,24]]},"references-count":57,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2016,10,25]]}},"alternative-id":["11566","27564101"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.11566","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,24]]}}}